MedTrace Logo

Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout

NCT04772352 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-02-26

No results posted yet for this study

Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases.

Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD.

This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD.

Conditions

  • Nonalcoholic Fatty Liver Disease

Interventions

DRUG

febuxostat treatment

According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)

BEHAVIORAL

lifestyle intervention

According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

Sponsors & Collaborators

  • Ningbo No. 1 Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-08-01
Completion
2022-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04772352 on ClinicalTrials.gov